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Type I Interferons (IFNs) are important cytokines
for innate immunity against viruses and cancer.
Sixteen human type I IFN variants signal through
the same cell-surface receptors, IFNAR1 and
IFNAR2, yet they can evoke markedly different phys-
iological effects. The crystal structures of two human
type I IFN ternary signaling complexes containing
IFNa2 and IFNu reveal recognition modes and heter-
otrimeric architectures that are unique among the
cytokine receptor superfamily but conserved
between different type I IFNs. Receptor-ligand
cross-reactivity is enabled by conserved receptor-
ligand ‘‘anchor points’’ interspersed among ligand-
specific interactions that ‘‘tune’’ the relative IFN-
binding affinities, in an apparent extracellular ‘‘ligand
proofreading’’ mechanism that modulates biological
activity. Functional differences between IFNs are
linked to their respective receptor recognition chem-
istries, in concert with a ligand-induced conforma-
tional change in IFNAR1, that collectively control
signal initiation and complex stability, ultimately
regulating differential STAT phosphorylation profiles,
receptor internalization rates, and downstream gene
expression patterns.INTRODUCTION
IFNs were the first cytokines discoveredmore than half a century
ago as agents that interfere with viral infection (Borden et al.,
2007; Isaacs and Lindenmann, 1957). IFNs have been estab-
lished as pleiotropic, multifunctional proteins in the early
immune response, exhibiting antiproliferative effects on cells,in addition to their strong immunomodulatory and antiviral activ-
ities. Due to their potency and diverse biological activities, IFNs
are used for the treatment of several human diseases, including
hepatitis C, multiple sclerosis, and certain types of cancer (Bor-
den et al., 2007). Based on the receptor system that mediates
their effects, IFNs are grouped into type I, type II, and type III
IFNs (Uze´ et al., 2007). The type I IFNs act on, and are produced
by, almost every nucleated cell and comprise 16 members with
approximately 20%–60% sequence identity: IFNb, IFN 3, IFNk,
IFNu, and 12 subtypes of IFNa. IFNa, IFNb, and IFNu are
produced by cells exposed to viruses or double-stranded RNA
(Garcı´a-Sastre and Biron, 2006) and have been shown to
possess antitumor activity (Horton et al., 1999; Pestka et al.,
2004) as well as protect cells against parasites and bacterial
pathogens (Bogdan, 2000). Although similar in their spectrum
of activities, IFNb, IFNu, and IFNa subtypes can vary signifi-
cantly in their potency against different viruses, their antiprolifer-
ative activity, and their ability to activate cells of the immune
system. The mechanism mediating this differential activity and
signaling through a common receptor remains controversial
(van Boxel-Dezaire et al., 2006).
Despite their differential activities and broad range of
potencies, all 16 human type I IFNs initiate signaling by bind-
ing to the same receptor composed of two subunits called
IFNAR1 and IFNAR2. Together with the IL-10 family receptors,
the IL-20 receptor, IL-22R, IL-22BP, IFNLR1, tissue factor,
and IFNGR, IFNAR1 and IFNAR2 form the class II helical
cytokine receptor family (Pestka et al., 2004; Walter, 2004;
Zdanov, 2010). In common with other class II helical cytokine
receptors, the extracellular domain (ECD) of IFNAR2, whose
nuclear magnetic resonance (NMR) structure has been char-
acterized (Chill et al., 2003), consists of two fibronectin III
(FNIII)-like domains (D1 and D2). The ECD of IFNAR1, how-
ever, is unique, comprising a tandem array of four FNIII sub-
domains, designated SD1 to SD4, which arose from gene
duplication of the typical two-domain structure (Gaboriaud
et al., 1990).Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc. 621
Figure 1. Differential Activities and Poten-
cies of Type I IFNs
(A) Antiviral dose-response curves of human
hepatoma (Huh7.5) cells transfected with genomic
hepatitis C virus (HCV) RNA and treated with
IFNa2(WT), IFNa2(YNS), IFNu, or IFNa7. Shown
are mean values with their standard deviation.
(B) Antiproliferative dose-response curves of
human amniotic epithelial (WISH) cells treatedwith
IFNa2(WT), IFNa2(YNS), IFNu, or IFNa7. Shown
are mean values with their standard error.
(C) Dose-response curves for STAT1 phosphory-
lation in monocytes from human whole blood, as
determined by phospho-flow analysis. Shown are
mean values with their standard error.
(D) Dose-response curves for STAT5 phosphory-
lation in monocytes from human whole blood, as
determined by phospho-flow cytometry analysis.
Shown are mean values with their standard error.
(E) IFNa2(YNS) more potently induces p-STAT1
than p-STAT3 or p-STAT5 in human primary
monocytes. Shown are mean values with their
standard error.
(F) Differential signaling properties of IFNa2(WT),
IFNa2(YNS), IFNu, and IFNa7 as evidenced by
different ratios of p-STAT1 to p-STAT5 EC50
values in different cell types from human whole
blood. Shown are mean values with their standard
error.
See also Figure S1.The intracellular domains (ICDs) of IFNAR1 and IFNAR2 are
associated with the Janus kinases (Jaks) Tyk2 and Jak1,
respectively (Schindler and Plumlee, 2008; van Boxel-Dezaire
et al., 2006). Upon ligand binding by the IFNAR chains and
formation of the extracellular signaling complex, these tyrosine
kinases initiate a phosphorylation cascade principally mediated
by STAT (signal transducer and activator of transcription) activa-
tion (Schindler and Plumlee, 2008). Other important signaling
pathways activated by type I IFNs include the phosphatidyl-
inositol 3-kinase pathway and the MAP kinase pathway. Studies
of the overlapping, yet differential cellular responses elicited by
different members of the type I IFNs (Uze´ et al., 2007) have
suggested that the dynamics of ligand interaction with the
receptor subunits plays a key role for regulating cellular
response patterns (Jaitin et al., 2006; Jaks et al., 2007; Kalie
et al., 2007).
There are currently no crystal structures of type I IFN receptor
complexes nor any complete receptor signaling complex in the
class II helical cytokine family where structures of binary com-
plexes of ligands (IFNg, IL-10, IL-22, IFNl) with their high-affinity
receptor subunits are known (Bleicher et al., 2008; Jones et al.,622 Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc.2008; Josephson et al., 2001; Miknis
et al., 2010; Walter et al., 1995). Here we
present structural and functional data
that shed light on how type I IFNs engage
their receptor chains, how the receptor
system is able to recognize the large
number of different ligands, and how the
different chemistries of ligand interactionultimately dictate the stabilities of the receptor complexes and
therefore exert primary control on differential signaling.
RESULTS
Type I IFNs Exhibit Distinct Signaling
and Functional Activities
We studied IFNs that differed significantly in their biological
activities: IFNu, IFNa2, and a mutant of IFNa2, IFNa2(YNS),
that was engineered to have higher affinity for IFNAR1 in order
to improve its antitumor efficacy (Kalie et al., 2007). We tested
their relative antiviral and antiproliferative potencies, as well
as another type I IFN, IFNa7 (Figures 1A and 1B and Figure S5
available online). The half-maximal effective concentration
(EC50) values in a hepatitis C replication assay showed 2- to
6-fold differences between the IFNs (IFNa7: 36 fM, IFNu:
37 fM, IFNa2(YNS): 20 fM, wild-type (WT) IFNa2: 116 fM) (Fig-
ure 1A), whereas the antiproliferative activities on WISH cells
differed by more than 1000-fold (EC50 values: IFNa7: 1700 pM,
IFNu: 490 pM, IFNa2(YNS): 1.5 pM, IFNa2(WT): 890 pM)
(Figure 1B).
Figure 2. Crystal Structures of Type I IFNReceptor Components and
Ligand-Receptor Complexes
Ribbon representations and designated resolutions of (A) IFNAR1DSD4; (B)
IFNAR2-D2; (C) the IFNa2(HEQ)-IFNAR2 binary complex (IFNa2(HEQ) brown,
IFNAR2 green); (D) ternary complex of IFNAR1 (blue), IFNAR2 (green), and
IFNa2(YNS); (E) ternary complex of IFNAR1 (blue), IFNAR2 (green), and IFNu.
The membrane-proximal SD4 domain of IFNAR1 is depicted as an oval.
See also Table S1 and Figure S2.We used phospho-flow cytometry coupled with fluorescent
cell barcoding to compare the intracellular signaling activities
of these IFNs by measuring phosphorylation of STATs in primary
cells in whole blood from human donors (Krutzik and Nolan,
2006). This approach enabled us to measure IFN responses on
endogenous IFN receptors of multiple cell subsets (B cells,
monocytes, and CD8 and CD4 T cells) simultaneously without
cell separation (Figures 1C–1F, Figure S1, and Figure S7).
Although the potency of the different IFNs in inducing phosphor-
ylation of STAT1 and STAT5 in monocytes is similar (Figures 1C
and 1D), IFNa2(YNS) has a lower EC50 for p-STAT1 induction
versus p-STAT3 and p-STAT5 (Figure 1E). Comparing the ratios
of EC50(p-STAT1) versus EC50(p-STAT5) reveals that the
different IFNs exhibit significant variability in different cell
subsets (Figure 1F), with IFNa2(YNS) displaying the highest ratio
of p-STAT1:p-STAT5 EC50 values in B cells, CD4 T cells, and
monocytes, and IFNu producing the lowest ratio in all three
cell subsets. Collectively, the cellular and signaling results high-
light the puzzling properties of differential signaling through the
common IFNAR1-IFNAR2 heterodimeric receptor.
The Architecture of the IFN Ternary Signaling Complex
We determined crystal structures of a range of individual IFN
receptor components, a subcomplex, and ternary complexes
at various resolutions (Figure 2 and Table S1): (1) the structure
of unliganded IFNAR1 comprising SD1 through SD3
(IFNAR1DSD4) at 1.9 A˚ (Figure 2A); (2) the IFNAR2-D2 domain
at 2.6 A˚ (Figure 2B); (3) the binary complex between IFNAR2
and IFNa2(HEQ) at 2.0 A˚ (Figure 2C); (4) the ternary ligand-
receptor complex of IFNa2(YNS) (hereafter also referred to as
IFNa2) at 4.0 A˚ (Figure 2D); (5) the ternary ligand-receptor
complex of wild-type IFNu at 3.5 A˚ (Figure 2E). IFNa2(YNS) is
a triple mutant (His57Tyr, Glu58Asn, Gln61Ser) of IFNa2 with
high affinity for IFNAR1, and HEQ is the triple mutant to alanine
(Jaitin et al., 2006). High-resolution structures of subcomponents
determined here, and previously (IFNa2 and IFNAR2-D1 domain)
(Quadt-Akabayov et al., 2006; Radhakrishnan et al., 1996), were
used to solve the ternary complexes. Despite their lower resolu-
tion, the electron density maps of the ternary complexes (Fig-
ure S2) allowed refinement of almost all amino acids and clear
visualization of conformational changes between the free and
bound states (details in Extended Experimental Procedures).
The SD4 of IFNAR1 has been shown to be unnecessary for IFN
binding (Lamken et al., 2005) and, consistent with electron-
microscopic studies (Li et al., 2008), it was not visible in the elec-
tron density maps. All structures can be viewed interactively at
(http://proteopedia.org/w/Journal:Cell:1).
IFNAR1 and IFNAR2 bind on opposing sides of the IFN ligands
in a nearly orthogonal architecture that has not been seen previ-
ously in crystal structures of cytokine-receptor complexes
(Figures 2D and 2E). Both the IFNa2 and IFNu complexes exhibit
almost identical overall receptor-ligand dockingmodeswhen the
two ternary complexes are superimposed (root-mean-square
deviation [rmsd] of Ca = 0.9 A˚) (Figure 3A). The IFNAR1-IFN
docking mode seen here is unusual and so far without precedent
among cytokine-receptor interactions. The IFNAR1-IFN inter-
face is formed by residues of the SD1, SD2, and SD3 subdo-
mains of IFNAR1 and by helices B, C, and D of the IFN molecule(Figures 2D and 2E), burying a total surface area of 2197 A˚2 (IFNu
ternary complex). The IFN ligand primarily binds to IFNAR1 at the
level of the hinge between the SD2 and SD3 domains, with the
SD1 domain ‘‘capping’’ the top of the IFN molecule. In prior
cytokine-receptor complexes of both the type I (e.g., human
growth hormone, interleukin-2, erythropoietin, etc.) and type II
(e.g., IFNg, IL-10, etc.) systems, the principal interaction mode
is between the cytokine and the loops projecting from the
‘‘elbow’’ formed between two bent Fibronectin-III (FNIII)
domains (Figure 3B) (Walter, 2004; Wang et al., 2009). In the
case of IFNAR1, the SD2-SD3 tandem FNIII domains appear to
be oriented in the opposite direction, such that the loops at the
extreme top and bottom ends of the FNIII domains form the
major contacts with the IFN ligands in a manner reminiscent of
pinchers, whereas the elbow loops that normally bind to cyto-
kines face outward into solvent. The SD1-SD2 tandem FNIII
module engages the ligands in a manner that is more represen-
tative of a canonical cytokine-binding mode where the elbow
contacts the ligand. As the SD1-SD2 and SD3-SD4 modules of
IFNAR1 most likely arose by gene duplication, the relative
orientation of the domains within the modules is thought to be
similar, allowing us to model a position for SD4 (Figure S3A).
However, its flexibility implies that there is interdomain variability
in its position on a cell surface.Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc. 623
Figure 3. Similar Architectures of Type I IFN Complexes Are Distinct
from Type II and Type III IFN Receptor Complexes
(A) The IFN molecules of the IFNu and IFNa2(YNS) ternary complexes were
superimposed and are shown in side view and top view. The rmsd for the
overall superposition of both structures is 0.9 A˚.
(B) The IFNu ternary complex is shown side-by-side with the IFNg-(IFNGR1)2
complex (PDB accession code: 1FG9) and the IFNl-IFNLR1 complex (PDB
accession code: 3OG6).
N, C: amino and carboxyl termini. SD1–SD3: subdomains of IFNAR1; D1,
D2: N- and C-terminal domains of IFNAR2. See also Figure S3B.
Figure 4. Specificity and Cross-reactivity Determinants between
IFN-IFNAR2
(A) Two different views of the IFNa2-IFNAR2 binary complex. Helices of IFNa2
are labeled A–E.
(B) Hotspot residues Leu30a2 and Arg33a2 of IFNa2 and their environment in
the interface with IFNAR2. Hydrogen bonds are shown as dashed lines.
(C) Close-up view of Arg149IFN, Glu77R2, and His76R2 and their environment.
Hydrogen bonds and salt bridges are depicted as dashed lines.
(D) Two-dimensional interaction map of the IFNa2-IFNAR2 interface. Amino
acids are depicted as nodes in the interaction maps (rectangles: IFNAR2;
ellipses: IFN). Interactions between side chains are represented by lines,
interactions between side chains and backbone are depicted as arrows
pointing toward the backbone. Van der Waals interactions and hydrophobic
contacts are shown as solid lines, H-bonds or electrostatic interactions as
dashed lines, and aromatic interactions as dotted lines. Residues shown in (B)
and (C) are bordered with a black line. Structural differences between the
IFNa-IFNAR2 and the IFNu-IFNAR2 interfaces are highlighted in red. IFNAR2
residues that, when mutated, differentially affect IFNa and IFNu binding are
encircled in orange.
(E) Two-dimensional interaction map of the IFNu-IFNAR2 interface.
See also Figure S2 and Table S2.On the opposing side of the ligand, both IFNAR2-IFN inter-
faces are formed between parts of helices A, E, and the A-B
loop of the ligand and the IFNAR2-D1 domain and the loop
between strands 13/14 in the D2 domain, burying 1841 A˚2
(IFNa2 binary complex) of surface area (Figures 2D and 2E and
Figure 4). On IFNAR2, the IFN ligand does not bind at the apex
of the elbow region between the D1 and D2 domains of IFNAR2
as seen in most type I and II cytokine-receptor complexes (Fig-
ure 3B), but rather almost all of the contact is with the receptor
D1 domain. In the ternary complexes, the long axis of the IFN
helical bundle is oriented perpendicularly to IFNAR1 but almost
parallel to the beta sheets of the IFNAR2 D1 domain. The overall
docking position of the ligands bound to IFNAR2 has global simi-
larities to the manner in which the IFNg dimer engages IFNGR1
(Walter et al., 1995) and also to the IFNl-IFNLR1 complex (Fig-
ure 3B) (Miknis et al., 2010). However, there are large differences
in the relative receptor-IFN binding orientations between the
different IFN types that clearly distinguish their recognition
modes (Figure S3B). The rigid body ligand-binding topology to
IFNAR2 is approximately similar to a docking model derived
using constraints from NMR and mutagenesis (Nudelman
et al., 2010).
Mechanism of IFN Cross-reactivity versus
Discrimination by IFNAR2
We compared the ligand-IFNAR2 interfaces from the binary
IFNa2-IFNAR2 complex (2.0 A˚ resolution) (Figures 4A–4D and
Figure S2) and the IFNu ternary complex (3.5 A˚ resolution)624 Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc.
Figure 5. Ligand-Induced Domain Movement in IFNAR1 and the
IFN-IFNAR1 Interfaces
(A) Domain movement in IFNAR1 upon IFN binding. Unliganded IFNAR1DSD4
(magenta) was superimposed onto subdomains 2 (SD2) and 3 (SD3) of IFNAR1
(blue) in the IFNu ternary complex. The difference in the position of the SD1
domain is depicted as an arrow. The ligand, IFNu, is shown with its molecular
surface. See also Figure S3 and http://proteopedia.org/w/Journal:Cell:1.
(B) Two different views of the IFNu ternary complex. SD1–SD3: subdomains of
IFNAR1; D1 and D2: subdomains of IFNAR2.
(C) Environment of the hotspot residues Tyr70R1 and Arg123u in the IFNAR1-
IFNu interface. Dashed lines symbolize hydrogen bonds and salt bridges.
(D) Hydrophobic and aromatic interactions between Leu134R1 and the hotspot
residue Phe238R1 in IFNAR1 and Phe67 in IFNu.
(E) The same region as in (D) in the IFNa2-IFNAR1 interface. Hydrogen bonds in
the close-up views are depicted as dashed lines.
(F) Interaction map of the IFNu-IFNAR1 interface in the IFNu ternary complex.
Amino acids are depicted as nodes in the interactionmap (rectangles: IFNAR1;
ellipses: IFNu) as used in Figure 4. Residues shown in (C), (D), and (E) are
bordered with a black line. IFNAR1 residues that, when mutated, differentially
affect IFNa and IFNu binding are encircled in orange.(Figure 4E and Figure S2). We elucidated interactions that are
conserved across type I IFNs (i.e., ‘‘anchor points’’) versus those
that would be ligand specific (Figure 4 and Figure 6). We also
assembled previous alanine scanning data (Kalie et al., 2007;
Piehler et al., 2000; Roisman et al., 2001, 2005), together with
new site-directedmutations prompted by the structures, in order
to reconcile the structures with comprehensive energetic maps
of the interfaces (Table S2). Overall, most of the residues
involved in the IFNa2-IFNAR2 interaction are also found in the
IFNu-IFNAR2 interface of the IFNu ternary complex (Figures
4D and 4E), highlighting that the basis of IFN cross-reactivity is
through conservation of interactions rather than through highly
divergent binding solutions. For clarity, in the two-dimensional
contact maps of Figure 4 and Figure 5, ligand-specific receptor
contacts are circled in red, whereas those with divergent muta-
tional consequences are circled in orange (Table S2). (Note:
due to nonidentical sequence lengths [Figure 6G], the numbering
of analogous IFNa2 and IFNu residues will often differ by one to
three residues throughout the paper.) For example, Arg33a2 (i.e.,
Arg35 in IFNu), which is conserved in IFNa, IFNu, IFNb, and IFN 3
(asparagine in IFNk), appears to be the single most important
residue for the interaction of both IFN ligands with IFNAR2
(Table S2; Figures 4B and 4D). It forms an extensive hydrogen-
bonding network with the main chain carbonyl oxygen atoms
of Ile45R2 and Glu50R2 and the side chain of Thr44R2. Replacing
Arg33a2 in IFNa2 by alanine destabilizes binding more than any
other mutation in IFNa2 (Table S2). Two hydrophobic interaction
clusters are present in the IFNa-IFNAR2 interface: the first one is
formed between Leu15a2 and Met16a2 of the IFN molecule and
Trp100R2 and Ile103R2 of IFNAR2; the second one comprises
Leu26a2, Phe27a2, Leu30a2, and Val142a2 of the ligand and
Met46R2, Leu52R2, Val80R2, and Thr44R2 of the receptor. Of
these, Trp100R2, Ile103R2, Met46R2, Val80R2, Thr44R2, and the
ligand residues corresponding to Met148a2, Phe27a2, Leu30a2,
and Val142a2 are also involved in the IFNu-IFNAR2 interface.
Substituting Met148a2 in IFNa2 or Ile103R2 of IFNAR2 results in
10- to 30-fold decreases in binding. As another example,
Leu30a2 is conserved in all human IFNs and equates to
Leu32u. Both are involved in similar hydrophobic clusters in
IFNAR2 interactions that are also energetically similar (Table
S2). Thus, these are energetically critical, shared anchor points
mediating IFN cross-reactivity.
In contrast, the mechanism of ligand discrimination appears to
derive in large part from differential energetics of shared contact
positions among the different IFNs. A major ligand-specific
difference between the IFNa and IFNu interfaces is related to
Arg149a2 in IFNa2, and the analogous Lys152IFN in IFNu, and
their respective interaction chemistries with Glu77R2. In the
IFNa2-IFNAR2 interface, these two residues (R149Aa2 and
Glu77R2) stabilize the interaction by forming a salt bridge
(Figures 4C and 4D) that is worth about 1.9 kcal/mol in free
energy (Figure S4). Substituting Arg149a2 by alanine reduces
the affinity between IFNa2 and IFNAR2 by two orders of magni-
tude (Table S2). Arginine at position 149 is the consensus in all
type I IFNs except IFNu, where it is replaced by Lys152u, that
forms an intramolecular salt bridge with Glu149u and is within
close proximity but is not directly contacting Glu77R2 of the
receptor. The differential contribution of Glu77R2 to the twoCell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc. 625
Figure 6. Conservation of Residues in the Ligand-Receptor Inter-
faces
(A–F) Residues on the surface of IFNu and IFNa involved in the interaction with
IFNAR1 (panel A: IFNa ternary complex, panel B: IFNu ternary complex) and
IFNAR2 (panel D: IFNa binary complex, panel E: IFNu ternary complex) are
colored light blue and green, respectively. Surface residues on IFNu
conserved between IFNs are shown in (C) and (F). Physicochemically
conserved amino acids are colored yellow; residues that are invariant in at
least four of five IFNs (IFNa2, IFNb, IFN 3, IFNk, and IFNu) are shown in red.
(G) Sequence alignment of human IFNs. Conserved and invariant residues are
colored as in (C) and (F). Interacting residues are denoted by rectangles below
the alignment, colored according to (A), (B), (D), and (E). Rectangles outlined in
black mark interacting residues in the IFNa2 binary complex. The secondary
structural elements of IFNu are depicted on top of the alignment.interfaces is reflected in the observation that its mutation to
alanine differentially affects IFNa and IFNu binding: The
IFNAR2(E77A) mutant binds IFNa2 with 60-fold lower affinity,
whereas the affinity toward IFNu is reduced only 10-fold (Table
S2, highlighted in orange). To mimic the connectivity of the
IFNa2-binding interface, we made the Lys152Argu swapping
mutation (in addition to K152A), which increases omega binding
by 5-fold (Table S2). To establish the connectivity of Arg at posi-
tion 152 in IFNu with Glu77R2, we performed double-mutant
cycle analyses between E77R2 and K152Au and K152Ru (Fig-
ure S4). Lysine152u binds Glu77R2 with a DDGint of 1.3 kcal/mol,626 Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc.whereas Arg in position 152 binds with a DDGint of 2.2 kcal/mol,
clearly establishing that, indeed, the consensus arginine at this
position is able to form a significantly stronger interaction, sup-
porting the respective structural organization observed for the
two different complexes. That the K152R substitution increases
binding in IFNu indicates that this position is a critical modular
hotspot for ligand discrimination and signaling (discussed
below).
There are additional examples of IFN sequence differences,
observed as receptor contacts in the structures, playing a role
in ligand subtype discrimination. Leu26a2 in IFNa2 equates to
Pro28u in IFNu (Figures 4D and 4E). The IFNu mutation P28Au
had no effect on receptor binding, whereas swapping Pro28u
with Leu26a2 (i.e., P28Lu) reduced binding 6-fold in IFNu.
Thus, these residues have evolved distinct energetic values by
substituting side chains. Another notable IFNAR2 contacting
residue that differs between alpha and omega (Table S2) is
Ala145a2, which is Met148 in IFNu. In alpha IFNs, alanine is the
consensus residue in position 145 (148 in u). Yet, M148Au
reduces binding by 2.5-fold. The complementary mutation of
Ala145 to Met in IFNa2 reduces binding by 6-fold. This shows
a distinct IFN-specific residue preference, and that this position
is not simply degenerate for apolar side chains. The subtle apolar
volume differences are keenly sensed in ligand discrimination.
On the receptor side, Val80R2 differentially affects IFNu versus
IFNa2 binding (Figures 4B, 4D, and 4E and Table S2, highlighted
in orange). Two other residues in IFNAR2, His76R2 and Met46R2,
also contribute to ligand discrimination (Table S2, highlighted in
orange).
IFNAR1 Forms a Diffuse and Broad Interface
with the IFN Ligand
The IFNu and IFNa2(YNS) complexes are essentially identical in
their binding footprints to IFNAR1 (Figure 3A and Figure 5). We
focus on the higher-resolution IFNu ternary complex for
a detailed description of the IFN-IFNAR1 interfaces (Figure S2).
When the unliganded IFNAR1DSD4 structure and IFNAR1 of
the ternary complexes are superimposed, it is apparent that
the N-terminal SD1 domain and the SD2-SD3 portion of IFNAR1
move relative to each other upon IFN binding (Figure 5A and
Figures S3C and S3D), allowing all three subdomains of IFNAR1
to contact the ligand. With the SD2-SD3 domains overlaid and
fixed, the conformational change upon complex formation is
a quasi-rigid body movement of the SD1 domain by about
10 A˚ down toward the ligand, bringing Asn68R1, Tyr70R1, and
Phe96R1 in contact with helix D of the IFN ligand (Figures 5A
and 5C). The aromatic rings of Tyr70R1 and Phe96R1, together
with the side chain of Leu131R1 in a loop of the SD2 domain,
form a hydrophobic patch that packs against the ligand (Figures
5C and 5F). Arg123u on helix D of IFNu forms a critical lynchpin
for the SD1-SD2 interaction: it hydrogen bonds to Ser182R1 in
the SD2 domain, contacts Thr181R1 and Phe96R1, and is
engaged in a salt bridge with Asp132R1 (Figures 5C and 5F).
Arg123u is intramolecularly stabilized by Glu61u that also forms
a hydrogen bond with Thr181R1. In addition, the IFNu-IFNAR1
interface is characterized by van der Waals and hydrophobic
interactions between Leu134R1 (SD2), Phe238R1 (SD3), and
Phe67u in helix B (Figures 5D and 5F). The interactions between
Leu134R1, Phe238R1, and the phenylalanine in the ligand
(Phe64a2 in IFNa) are conserved in the IFNa-IFNAR1 interface
(Figure 5E). Moreover, the contact between His236R1 and an
aspartate in the ligand is common to the interfaces of both
IFNs (Figures 5D and 5E).
It has been demonstrated that the three N-terminal FNIII
domains of IFNAR1 (SD1–SD3) are necessary and sufficient for
ligand binding (Lamken et al., 2005). In particular, the SD1
segment spanning residues 62–70 is crucial for ligand binding
and biological activity, with Val69R1 and Tyr70R1 as key residues
(Cajean-Feroldi et al., 2004). Their role is revealed by our ternary
complex structures: Tyr70R1 directly contacts the ligand (Figures
5C and 5F), whereas the preceding Val69R1 stabilizes the S3-S4
loop. Tyr70R1 and F238R1 are the only hotspot residues in the
ligand-binding site of IFNAR1 (Table S2), highlighting its compar-
atively energetically flat binding surface compared to IFNAR2.
Substituting these residues by alanine reduces the affinity to all
tested IFN ligands by more than 10-fold (Table S2).
Most interactions of the IFNu-IFNAR1 interface are conserved
in the IFNa2-IFNAR1 interface (Figures 5D and 5E and Figures
6C and 6G). Differences include an aromatic interaction
between Tyr157R1 of the receptor and Tyr89a2 of IFNa2. In
IFNu, Tyr157R1 hydrogen bonds to Gln96u (Figures 5D and
5E). Furthermore, Tyr85a2 and Tyr89a2 participate in the hydro-
phobic interaction with Leu134R1 and Phe238R1 of IFNAR1
and Phe64a2 of the ligand (Figure 5E); His71u, which is contact-
ing Asn242R1 in the IFNu complex, is replaced with a serine in
IFNa2. The different chemical environments of Asn242R1 in
the two complexes might contribute to ligand specificity
(Table S2, highlighted in orange).IFNs Are Discriminated through Ligand-Specific
Substitutions
In order to analyze the cross-reactivity of the type I IFN receptor,
we mapped the interface contact residues and the residues
conserved between IFNa2, IFNu, IFNb, IFN 3, and IFNk onto
the surface of the IFN molecules in the ternary complexes (Fig-
ure 6). A comparison of the maps of contact residues with the
degree of sequence conservation reveals that IFNAR1 and
IFNAR2 cross-react with different IFNs by using a few conserved
residues on their ligands as anchor points against a background
of less- or nonconserved amino acids (Figures 6C, 6F, and 6G).
As our mutational analysis has shown, ligand discrimination
occurs primarily through distinct energetics of common contacts
but also through small numbers of IFN subtype- or sequence-
specific contacts. The invariant and conserved ligand residues
comprise Leu32u, Arg35u, Val145u, Arg147u, Glu149u,
Lys152u, and Leu156u in the IFNAR2 interface and His60u,
Glu61u, Gln64u, Gln65u, Phe67u, Gln93u, Gln96u, Leu102u,
Leu120u, and Arg123u in the IFNAR1 interface (residues and
numbering referring to IFNu). Of the invariant and conserved
IFN residues that form direct contacts with the receptor chains,
Leu32u, Arg35u, Leu156u, His60u, Glu61u, Gln64u, Phe67u,
and Arg123u influence the energetics of the ligand-receptor
interaction, indicated bymutational studies of the corresponding
residues in IFNa2 (Leu30a2, Arg33a2, Leu153a2, His57a2,
Glu58a2, Gln61a2, Phe64a2, and Arg120a2; see Table S2).Probing Differential IFN Signaling with Structure-Based
Mutational Analysis
We analyzed two types of IFN mutations for their effects on
signaling and function. We chose residues that differ in identity
between IFNa2 and IFNu and either directly make energetically
important receptor contacts in the structures or are in close
proximity to residues that do. The first group includes Ala
mutations of these residues (L26Aa2/P28Au, L30Aa2/L32Au,
A145Ga2/M148Au, R149Aa2/K152Au), as well as swaps of ener-
getically important ‘‘sister’’ residues that are in corresponding
positions (P28Lu, K152Ru). A second group of mutations was
designed to change the binding affinity to both receptors
simultaneously. These were based on the IFNa2(YNS) variant
(increases binding to IFNAR1 by 60-fold) and include
YNS/M148A and YNS/L153A, which reduce binding to IFNAR2
by 30- and 10-fold, respectively (Table S2). Proteins harboring
both mutations will have an altered balance between their affin-
ities to IFNAR1 (higher affinity) and IFNAR2 (lower affinity). The
mutant-binding affinities are shown in Table S2. This extended
set of mutations was then used to assess a range of functional
consequences of IFN binding to the IFNAR1-IFNAR2 receptors:
(1) antiviral (AV) and antiproliferative (AP) activity (Figure 7 and
Figure S5), (2) p-STAT activation with respect to EC50s and their
relative ratios in different cell types fromwhole blood (Figures 8A
and 8B and Figure S7), (3) gene expression (PKR, CXCL11, and
TRAIL) in WISH cells (Figure 8A and Figure S6), and (4) receptor
internalization (Figure 8C).
Antiviral and Antiproliferative Activity
Structure-based mutations that result in loss of binding affinity
also lead to a decrease in potency for both AV and AP activities
and consequently reduce the functional distinction between
IFNs (Figure 7 and Figure S5). These data are in general accord
with the stability model—antiviral activity is less affected by
a loss in binding affinity than antiproliferative activity. Strikingly,
mutations increasing binding affinity, as the ones observed for
the mutants IFNa2(YNS) and IFNu(K152R), result in a significant
increase of the AP activity, but not AV activity (Figure 7B).
Indeed, the IFNu(K152R) gain-of-function mutant shows that
a single substitution of the corresponding a2 residue results in
IFNu behaving more like IFNa2(YNS). This supports the model
that IFN-specific polymorphisms engaged in receptor contacts
that energetically mediate complex stability play a major role in
modulating IFN-specific functional activities (Figure 7B). These
results also imply that intermediate affinities are sufficient to
induce a maximal AV response, whereas much higher affinities
are required to reach the maximal AP potency—in this respect
the AP response is more ‘‘tunable’’ (Levin et al., 2011).
p-STAT Activation
We used phospho-flow cytometry and fluorescent cell barcod-
ing to measure phosphorylation levels of STAT1, 3, 4, and 5 in
whole blood samples from two human donors (Figures 8A and
8B and Figure S7). Similar to the AV activity, the EC50 values
obtained for p-STAT activation proportionally increased for
weaker binding mutants, whereas for the high-affinity mutants
(IFNa2(YNS) and IFNu(K152R)) the same trend was not
observed. Indeed, although IFNa2(YNS) induced slightly
stronger STAT activation than IFNa2(WT), these differences
were very small relative to their very substantial differences inCell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc. 627
Figure 7. Correlation between Complex Stability and Functional
Activity
(A) Antiviral and antiproliferative activity of IFNa2 and IFNumutants relative to
IFNa2(WT) and IFNu(WT), respectively. As a measure of complex stability, the
product of the affinities toward IFNAR1 and IFNAR2 was calculated and
divided by the value of the respective wild-type protein.
(B) Direct comparison of the antiviral and antiproliferative activity (EC50 values)
of the high-affinity mutants IFNa2(YNS) and IFNu(K152R) and the corre-
sponding wild-type proteins.
See also Figure S5.affinity. Similarly, with the IFNu(K152R) mutant, despite its
higher binding affinity, this mutant is somewhat less potent in
p-STAT activation than IFNu(WT). These results are in accord
with the current model that AV activity is well correlated with
early p-STAT activation, and AV activity is nearly maximal even
for weak binders. In contrast, the extent of STAT activation is
not sufficient to explain the potency of the AP response.
p-STAT Ratios
Variable ratios of STAT activation in cell subsets is a striking
example of differential signaling through a common receptor
by different IFN subtypes (Figure 1F). We analyzed the p-STAT
activation ratios induced by the high-affinity IFNa2(YNS) and
IFNu(K152R) mutants, as well as the wild-type IFNs, IFNa2
and IFNu, in a mixed population of immune cells, i.e., whole
blood samples from humans (Figure 8B and Figure S7). Both
mutants followed the same trend in deviations of p-STAT ratios
relative to the wild-type IFNs, supporting the idea that by
substituting a critical contact residue from one IFN into another,
we have narrowed their functional distinction. As the principal628 Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc.effects of these substitutions are on affinity, this further suggests
that the stability of the complex is the key determinant for func-
tional distinction of IFNs and also highlights the utility of this
metric as a readout of differential signaling activities by IFNs.
Receptor Internalization
We hypothesized that rapid receptor downregulation could be
responsible for the nonproportional p-STAT activation observed
for IFN mutants with increased binding affinity. Increased
IFNAR2 downregulation by an IFNa2 mutant with increased
binding affinity toward IFNAR1 has been observed (Jaitin et al.,
2006; Marijanovic et al., 2007). Here we show that mutants
exhibiting higher binding affinity for IFNAR2 than WT induced
a stronger IFNAR2 downregulation (Figure 8C) and faster
decrease in p-STAT activation (Figure 8D). The IFNa2(YNS)
reduced IFNAR2 by 60%, whereas the K152Ru mutant almost
completely eliminated surface IFNAR2, as opposed to wild-
type IFNa2 or IFNu that only reduced the surface IFNAR2 by
50% (Figure 8C). Thus, increased binding affinities increase
the propensity for receptor endocytosis, which leads to faster
termination of signaling. The substantially stronger IFNAR2
downregulation exhibited by K152Ru may explain the surprising
increase in EC50 of p-STATs seen for this mutant (Figure 8A) due
to more rapid (Figure 8C) receptor inactivation in the endosome.
Gene Expression
We asked how receptor-binding affinity regulates the IFN-
induced gene expression program. By rtPCR, we measured
the levels of PKR, CXCL11, and TRAIL induction following 8 hr
of treatment with the different IFN mutants (Figure 8A and Fig-
ure S6—note that P28Au and M148Au were not included in the
gene expression analysis). We found a uniform correlation
between receptor-binding affinity and gene expression levels.
That is, mutants with reduced affinity had a higher EC50 for
induction of PKR, CXCL11, and TRAIL genes, whereas mutants
with higher affinity had a lower EC50 for induction of these genes.
These data also indicate that the extent of STAT activation as
measured by tyrosine phosphorylation does not fully explain
the level of gene expression and AP response induced by the
different IFN mutants, as in the case of the YNS and K152Ru
mutants. Although YNS is only marginally more potent in acti-
vating STATs than IFNa2(WT), it is significantly more potent in
inducing TRAIL, PKR, and CXCL11 than IFNa2(WT). Interest-
ingly, whereas the EC50 for PKR gene expression activation
is50-fold lower for most IFNs than the onemeasured for TRAIL
or CXCL11, these ratios are significantly smaller (15-fold) for
the three YNSa2 variants and for the K152Ru mutant (Figure S6),
suggesting that tighter-binding IFNs lose some of this differential
gene activation, perhaps by sacrificing tunability for affinity.
DISCUSSION
Type I interferons were discovered over 50 years ago as antiviral
agents. Subsequent research has shown that the many IFN
subtypes show differential activities through common receptor
chains. Our studies show that the overall architectures of
receptor binding to both IFNa2 and IFNu are nearly identical
(Figure 3A), and that the answer to how different IFNs are
capable of inducing differential functional effects appears to
be ligand discrimination through distinct receptor-binding
Figure 8. Relationship between STAT Phosphorylation, Gene Expression, and Receptor Downregulation to IFN Mutant-Binding Affinities
(A) Complex stabilities and induction of STAT phosphorylation in CD4 T cells and gene expression (protein kinase R [PKR], tumor necrosis factor-related
apoptosis-inducing ligand [TRAIL], chemokine CXCL11) by IFNa2 and IFNu mutants relative to wild-type IFNa2 and IFNu, respectively.
(B) Different EC50(p-STAT) ratios for IFNa2(YNS), IFNu(K152R), IFNa2(WT), and IFNu(WT) in different cell subsets of whole blood from human donors. IFNa2(YNS)
and IFNu(K152R) show the same trend of ratio deviations from the wild-type proteins.
(C) Expression levels of IFNAR2 on the surface of B cell lymphoma (Ramos) cells 5 min after stimulation with IFNa2 and IFNu proteins. Shown are mean values
with their standard error.
(D) Time course of decrease of p-STAT3 activation induced by different IFNa and IFNu proteins.
See also Figure S6 and Figure S7.chemistries, which dictate the respective stabilities of the
receptor-ligand interactions. The distinct binding chemistries
are achieved primarily by differential energetics of shared anchor
points and, to a lesser extent, by key amino acid substitutions
between IFNs. These ligand-specific differences in the extracel-
lular complex stabilities manifest as perturbations in down-
stream signaling cascades, in both linear and nonlinear fashions.
Mechanistically, different complex stability kinetics could control
the relative Jak/Tyk activity toward intracellular substrates of
greater or lesser accessibility, which would in turn lead to distinct
downstream effector activation profiles and ultimately impact
induction of IFN-responsive genes. In this respect, recognition-mediated tuning of differential signaling by the type I IFN
receptor system is quite unique for a transmembrane receptor
but has parallels to the antigen ‘‘proofreading’’ ability of the
T cell receptor to differentially respond to self and foreign
peptide-MHC molecules presenting subtly different peptide
recognition chemistries.
In the context of prior cytokine receptor structures, IFNAR1 is
particularly striking, with participation of three subdomains and
a conformational change upon IFN binding (Figure 5A and Fig-
ure S3). That this is a bona fide ligand-induced conformational
change is corroborated by the importance of the SD1 domain
for ligand binding and by FRET measurements suggestingCell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc. 629
conformational changes in the ectodomain of IFNAR1 upon IFN
binding (Strunk et al., 2008). The conformational change in
IFNAR1 is required to form the full spectrum of interactions
with the ligand and to allow the formation of a ternary complex
that is stable enough to facilitate transphosphorylation between
Jak1 and Tyk2. Thus, ligand binding to IFNAR1 will be accompa-
nied by an energetic cost associated with the structural rear-
rangements required to bring a key hotspot residue into contact
and could play a role in tuning responsiveness to different IFN
ligands. We suggest that the required conformational change
contributes to the reduced binding affinity of IFNAR1 and may
result in tighter control of IFN signaling.
In addition to the conformational change, the role of IFNAR1 in
ligand responsiveness is also unique compared to IFNAR2.
IFNAR1 is not optimized for high binding affinity but rather for
functional plasticity. That is, in contrast to the interaction with
IFNAR2, binding energy is distributed over a large number of
amino acid contacts with relatively low individual contributions
and with much lower cooperativity, altogether resulting in lower
affinity. For early STAT activation, which is required for the
antiviral cellular response, transient ligand interaction with
IFNAR1 appears to be advantageous (Moraga et al., 2009).
High stability of the ternary complex seems to bemore important
for a subset of IFN activities requiring prolonged activation of IFN
signaling pathways (Coelho et al., 2005; Jaitin et al., 2006). The
relatively large binding interface of IFNAR1 for IFN involving three
FNIII-like domains provides a versatile means for fine-tuning the
binding affinity toward different IFNs and tailoring differential
response patterns.
The molecular basis of IFNAR cross-reactivity is unique
compared with other shared receptor systems, such as gp130
and common gamma chain (gc), and this likely reflects the
fact that the IFN interaction chemistry controls signal initiation.
gp130 engages different cytokines through entirely distinct
binding surfaces that do not appear to share anchor points,
whereas gc engages in degenerate binding largely through
shape complementarity (Wang et al., 2009). What sets the
IFNAR system apart is that the IFNAR1/2 heterodimer recog-
nizes and transduces the signal for all 16 IFN subtypes, whereas
in the other shared cytokine receptors, signal specificity is
determined by different ligand-specific coreceptors hetero-
dimerizing with the shared receptor. In this way, the recognition
chemistries of gp130 and gc are not important arbiters of
signaling specificity.
With regards to function, our mutational and substitution
experiments suggest a model whereby ablating or swapping
key IFN-specific residues that engage in receptor interactions
narrows the functional distinction between IFNs. Importantly,
however, the mutational analysis also shows that the local
environment of these contacts plays an important role in deter-
mining their energetic values in the respective IFN complexes.
Mutation of individual positions has complicated energetic
consequence. Therefore, ligand-specific residues are not ‘‘plug-
and-play’’ in a manner that easily allows one to recapitulate IFN
subtype behavior by point mutagenesis. This is to be expected
given that the functional distinction of IFN ligands arose, in
part, through coevolution of broad receptor-ligand interaction
surfaces over hundreds of millions of years. A surprising excep-630 Cell 146, 621–632, August 19, 2011 ª2011 Elsevier Inc.tion to this was the K152R gain-of-function mutation in IFNu,
which, clearly, is a highly modular contact point.
Ligand-specific differences in the stabilities of the complexes
are also reflected in variances in the kinetics of receptor down-
regulation, which terminates signaling. Our studies revealed
that increased binding affinities toward IFNAR1 (IFNa2(YNS)
mutant) or IFNAR2 (IFNu(K152R) mutant) strongly enhance
receptor downregulation, which very likely explains a much
more rapid decline in p-STAT activation compared to IFNa2(WT)
and IFNu(WT). Increased IFNAR2 downregulation by the higher-
affinity IFNb, compared to IFNa2, has been previously suggested
to be responsible for differential cellular responses (Jaitin et al.,
2006; Kalie et al., 2007). Here, we have designed an IFN mutant
with increased binding affinity toward IFNAR2, which surpris-
ingly induces even stronger downregulation of IFNAR2.
Increased IFNAR2 downregulation could explain why the
substantially increased binding affinity of these IFN mutants is
not accompanied by a significant increase in their AV potency
because it is very likely responsible for a rapid decrease in
p-STAT levels, as seen after stimulation with IFNa2(YNS) and
IFNu(K152R).
In contrast to AV activity, which requires only very low doses of
IFN to reach saturation, AP activity benefits from an increased
binding affinity (Kalie et al., 2008). Cells need to sense very low
levels of IFN and act very fast in order to clear viral infections
in their initial stages. On the other hand, antiproliferative activity,
which is often linkedwith apoptosis and tissue damage, needs to
be under tighter control to prevent unnecessary damage. These
activities will therefore be more tunable over a broad range to
changes in the kinetics and strength of the downstream
signaling. IFNs, by forming a gradient of complex stabilities,
will induce specific profiles of signal activation that will lead to
diverse antiproliferative potencies. Taken together, differential
IFN signaling activities are mediated by both nonlinear signaling
and nonlinear receptor desensitization mechanisms. This type of
‘‘ligand proofreading’’ provides a mechanistic model, now
together with a structural framework, for how a common
receptor can respond in a graded fashion to different ligands.
EXPERIMENTAL PROCEDURES
Transient Hepatitis C Virus Replication Assay
The transient hepatitis C virus (HCV) replication assay was performed using
Huh7.5 cells and a Luciferase reporter system as previously described
(Cho et al., 2010). Additional details for this and subsequent experimental
procedures can be found in the Extended Experimental Procedures.
Antiproliferative Activity Assay
Antiproliferative assays were performed usingWISH cells as described inMor-
aga et al. (2009).
Protein Expression, Purification, and Complex Formation
The following proteins used in this study were expressed as C-terminally
his-tagged constructs from baculovirus using the pAcGp67A vector: human
IFNu (including all IFNu mutants), IFNa7, IFNa2(HEQ), IFNAR1DSD4 (amino
acids 3–305), full-length IFNAR1 ectodomain, IFNAR2 (amino acids 10–205),
IFNAR2-D2 (amino acids 104–205). IFNAR2 used in the binary complex was
secreted by Hi-5 cells in the presence of Tunicamycin at a concentration of
0.5 mg/l. IFNAR2 (amino acids 7–205) used for IFNu(N80Q) ternary complex
formation was expressed using the BacMam expression vector pVL-AD6-L
(Dukkipati et al., 2008) from suspended HEK293 GnTI cells grown in Pro293
medium and was deglycosylated with endoglycosidase Hf. Human IFNa2 and
all IFNa2 mutants, except HEQ, were expressed in E. coli according to
published methods (Kalie et al., 2007). Prior to crystallization, all proteins
were treated with 3C protease/TEV protease and/or carboxypeptidases A
and B to remove C-terminal his-tags. Selenomethionine (SeMet)-labeled
proteins from baculovirus were prepared according to a protocol published
earlier (Dong et al., 2009).
The IFNu(N80Q) ternary complex was formed by mixing IFNAR1 and
IFNu(N80Q) from insect cells with IFNAR2 expressed in HEK293 cells. The
IFNa2(YNS) ternary complex was formed by mixing IFNAR1 and IFNAR2
from insect cells and IFNa2(YNS) expressed in E. coli. The complexes were
formed by mixing individually purified components in approximately stoichio-
metric ratios; the complexes were purified by gel filtration.
Crystallization and X-Ray Data Collection
All crystallization experiments were carried out using hanging-drop vapor
diffusion at 20C. Individual crystallization conditions can be found in the
Extended Experimental Procedures.
Datasets on frozen crystals were collected at beamlines 9.1 (SeMet-
IFNAR1DSD4), 9.2 (osmium-derivatized IFNAR1DSD4; SeMet-IFNAR2-D2),
and 11.1 (native dataset of IFNAR1DSD4) of the Stanford Synchrotron Radia-
tion Lightsource (SSRL) and at beamlines 8.2.1 (IFNa2(YNS) ternary complex)
and 8.2.2 (IFNa2(HEQ)-IFNAR2 binary complex; IFNu(N80Q) ternary complex)
of the Advanced Light Source (ALS), Berkeley. All data were indexed, inte-
grated, and scaled with the XDS package (Kabsch, 1993).
Structure Determination and Refinement
Phases for IFNAR1DSD4 were obtained by single isomorphous replacement
with anomalous scattering (SIRAS) in the program autoSHARP (Vonrhein
et al., 2007) using the osmium derivative and the native dataset.
The structure of the SeMet-labeled IFNAR2-D2 domain was determined by
single-wavelength anomalous diffraction (SAD) using autoSHARP.
The IFNa2(HEQ)-IFNAR2 binary complex, IFNa2(YNS) ternary complex, and
IFNu(N80Q) ternary complex were all solved by molecular replacement with
the program Phaser (McCoy et al., 2007). All X-ray structures described
were refined with Phenix (Adams et al., 2010). Molecular graphics images
were prepared using PyMOL (Schro¨dinger).
Affinity Measurements
All binding data of IFNs and the ECD of IFNAR2 were determined by surface
plasmon resonance on a ProteOn XPR36 machine (BIO-RAD) using purified
proteins. Binding of IFNa2(YNS) and IFNu to immobilized IFNAR1 was probed
by simultaneous total internal reflection fluorescence spectroscopy (TIRFS)
and reflectance interference (RIF) detection.
Phospho-Flow Analysis of Intracellular Signaling
Analysis of intracellular signaling in whole blood was performed as previously
described (Krutzik and Nolan, 2006). Briefly, whole blood samples from two
donors were warmed to 37C and stimulated with increasing concentrations
of the appropriate cytokine for 30 min. After samples were fixed and lysed,
samples were fluorescently barcoded with DyLight 800 and Pacific Orange
dyes as previously described. After barcoding and combining, samples were
stained for 1 hr with CD3 PE, CD4 Pacific Blue, CD20 PerCP-Cy5.5, CD33
PE-Cy7, and a combination of p-STAT1 Ax647 and p-STAT3 Ax488 or
p-STAT5 Ax647 and p-STAT4 Ax488. Analysis was performed on a Becton
Dickinson LSRII equipped with 405, 488, and 633 nm lasers. Data analysis
was performed in Cytobank software. Log median fluorescence intensity
values were plotted against cytokine concentration to yield dose-response
curves.
Analysis of IFNAR2 Downregulation
Downregulation experiments were performed using Ramos cells stimulated
with IFN proteins for 5 min, followed by anti-IFNAR2 monoclonal antibody
(mAb) staining as described in Jaitin et al. (2006) and Marijanovic et al. (2007).Analysis of STAT Phosphorylation Kinetics
Ramos cells were stimulated with 10 nM of IFNmutants for the indicated times
according to the protocol in Marijanovic et al. (2007). Samples were analyzed
by phospho-flow cytometry.
Quantitative PCR
Selected human IFN-stimulated gene expression levels were measured with
the ABI Prism 7300 Real-Time PCR System using previously described
methods (Levin et al., 2011).
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